Leitlinie
ATA 2025 DTC Guidelines: De-escalating Therapy and Monitoring
Clinical Thyroidology® · 01.07.2026 · 38 (7) · 223-226
DOI: 10.1177/23299711261466452 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical Thyroidology®, online erschienen am 13.07.2026. Verfasst von Jennifer S. Mammen. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
histopathology, clinical background, and initial tumor staging data
Zitieren
APA
Mammen, J. S. (2026). ATA 2025 DTC Guidelines: De-escalating Therapy and Monitoring. Clinical Thyroidology®, 38(7), 223-226. https://doi.org/10.1177/23299711261466452
Vancouver
Mammen JS. ATA 2025 DTC Guidelines: De-escalating Therapy and Monitoring. Clinical Thyroidology®. 2026;38(7):223-226. doi:10.1177/23299711261466452
BibTeX
@article{Mammen2026,
author = {Mammen, Jennifer S.},
title = {ATA 2025 DTC Guidelines: De-escalating Therapy and Monitoring},
journal = {Clinical Thyroidology®},
year = {2026},
volume = {38},
number = {7},
pages = {223--226},
doi = {10.1177/23299711261466452}
}
EUVIMED